The Boeing Company (BA)vsPfizer Inc (PFE)
BA
The Boeing Company
$199.61
+1.62%
INDUSTRIALS · Cap: $154.36B
PFE
Pfizer Inc
$27.28
+1.19%
HEALTHCARE · Cap: $153.36B
Smart Verdict
WallStSmart Research — data-driven comparison
The Boeing Company generates 43% more annual revenue ($89.46B vs $62.58B). PFE leads profitability with a 12.4% profit margin vs 2.5%. BA appears more attractively valued with a PEG of 6.53. BA earns a higher WallStSmart Score of 51/100 (C-).
BA
Buy51
out of 100
Grade: C-
PFE
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1083.9%
Fair Value
$16.86
Current Price
$199.61
$182.75 premium
Margin of Safety
-194.9%
Fair Value
$9.25
Current Price
$27.28
$18.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 57.1% year-over-year
Large-cap with strong market position
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Generating 4.5B in free cash flow
Areas to Watch
ROE of 2.9% — below average capital efficiency
2.5% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Revenue declined 1.2%
Earnings declined 21.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BA
The strongest argument for BA centers on Revenue Growth, Market Cap. Revenue growth of 57.1% demonstrates continued momentum.
Bull Case : PFE
The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.
Bear Case : BA
The primary concerns for BA are Return on Equity, Profit Margin, PEG Ratio. A P/E of 79.2x leaves little room for execution misses. Debt-to-equity of 9.92 is elevated, increasing financial risk.
Bear Case : PFE
The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
BA profiles as a hypergrowth stock while PFE is a declining play — different risk/reward profiles.
BA carries more volatility with a beta of 1.10 — expect wider price swings.
BA is growing revenue faster at 57.1% — sustainability is the question.
PFE generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
BA scores higher overall (51/100 vs 49/100) and 57.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
The Boeing Company
INDUSTRIALS · AEROSPACE & DEFENSE · USA
The Boeing Company is an American multinational corporation that designs, manufactures, and sells airplanes, rotorcraft, rockets, satellites, telecommunications equipment, and missiles worldwide. The company also provides leasing and product support services.
Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Compare with Other AEROSPACE & DEFENSE Stocks
Want to dig deeper into these stocks?